Worth reading
26Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Who is moving to which position
Resolved 15 May 2026Incoming appointee
2 itemsScheduled Appointment DateEffective 25 June 2026. The new director and new audit & supervisory board member are expected to take office following approval at the ordinary general meeting of shareholders scheduled for the same date.
Mochida Kenji (持田 健志)
Previous positionExecutive Officer, Deputy General Manager of the Pharmaceutical Development Division, responsible for Development Planning and Medical Affairs
New positionDirector, Senior Executive Officer, responsible for Business Development and Business Promotion
Nakano Reiko (中野 玲子)
Previous positionDeputy General Manager of the Business Development Division
New positionFull-time Audit & Supervisory Board Member
Departing officer
2 itemsDate of departureEffective 25 June 2026
Kawakami Yutaka (川上 裕)Next role stated
Former PositionDirector, Senior Executive Officer, responsible for 持田製薬工場 and Mochida Healthcare
New positionAdviser
Takeda Masayoshi (竹田 雅好)Next role stated
Former PositionFull-time Audit & Supervisory Board Member
New positionAdviser
“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.
Whether the incumbent will remain in office (whether they will retain their position)
Will not remain on the Board of Directors
Shareholders’ meeting approvalApproval of the director nominee and audit & supervisory board member nominee at the ordinary general meeting of shareholders scheduled for 25 June 2026
| Item | Details |
|---|---|
| Resolution date | 15 May 2026 |
| Scheduled Appointment Date | Effective 25 June 2026. The new director and new audit & supervisory board member are expected to take office following approval at the ordinary general meeting of shareholders scheduled for the same date. |
| Date of departure | Effective 25 June 2026 |
| Name of appointee | Mochida Kenji (持田 健志), Nakano Reiko (中野 玲子) |
| Appointee's new position | Director, Senior Executive Officer, responsible for Business Development and Business Promotion, Full-time Audit & Supervisory Board Member |
| Appointee's previous position | Executive Officer, Deputy General Manager of the Pharmaceutical Development Division, responsible for Development Planning and Medical Affairs, Deputy General Manager of the Business Development Division |
| Name of departing officer | Kawakami Yutaka (川上 裕), Takeda Masayoshi (竹田 雅好) |
| Former position of departing officer | Director, Senior Executive Officer, responsible for 持田製薬工場 and Mochida Healthcare, Full-time Audit & Supervisory Board Member |
| New position of departing officer | Adviser, Adviser |
| Whether the incumbent will remain in office | Will not remain on the Board of Directors |
| Subject to Approval by the General Meeting of Shareholders | Approval of the director nominee and audit & supervisory board member nominee at the ordinary general meeting of shareholders scheduled for 25 June 2026 |
Items this document does not state (10)
Appointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeReason for departureReason for changeReasons for appointmentNumber of directors after the changeFiling as an independent officerDetails of organizational changesChange in Corporate Governance Structure
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.No specific reason for the changes is stated.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.